Astrazeneca PLC (AZN) has been under a strong bear grip, hence the stock is down -2.7% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.28% in the past 1 week. The stock has risen by 0.79% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.83% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 0.51% and the 50-Day Moving Average is 5.08%.The 200 Day SMA reached 10.53%. AstraZeneca PLC is up 13.01% in the last 3-month period. Year-to-Date the stock performance stands at 2.64%.
Astrazeneca PLC (NYSE:AZN): After opening at $33.08, the stock dipped to an intraday low of $32.96 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $33.4769 and the buying power remained strong till the end. The stock closed at $33.31 for the day, a gain of 2.18% for the day session. The total traded volume was 3,646,805. The stocks close on the previous trading day was $32.6.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).